EFSA consults on BPA risk to human health
Published 24 Jan 2014
The European Food Safety Authority (EFSA) has published its draft assessment of the human health risks posed by exposure to Bisphenol A (BPA). They conclude that BPA is “likely” to have effects on the liver, kidney and mammary gland and has recommended that the Tolerable Daily Intake (TDI) for the chemical be reduced by 90%. However, despite concerns about the adverse health effects of BPA, EFSA also conclude that overall levels of human exposure are safe. Breast Cancer UK overwhelmingly reject this conclusion.
Numerous scientific studies show that BPA has the ability to transform normal breast cells into cells of a more cancerous or overall malignant nature, that it can trigger DNA strand breaks, interfere with cell division and interfere with chemotherapy, making it less effective against breast cancers.
EFSA's decision to temporarily reduce the so-called Tolerable Daily Intakes (TDIs) for BPA provides a veil of safety over the chemical, and could be used to justify its continued use in food and drinks packaging and other products. Breast Cancer UK believe that the decision to base the suggested TDI on just one study is flawed and ignores other data that indicates BPA is harmful, even at very low levels of exposure.
BPA gives rise to ‘non monotonic’ dose responses, which means that it has varying effects at different doses. Therefore, the application of TDIs of BPA, predicted from higher doses to permit its continued use in products, is likely to be unsafe for the consumer.”
Breast Cancer UK will submit a response to EFSA’s public consultation on the human health impacts of BPA.